A new study has paved the way for a promising vaccine for the Zika virus. Preclinical results of research by City College of New York scientists and TechnoVax Inc. in animal models demonstrated favourable outcomes in developing a vaccine against the mosquito-borne Zika virus. The results were announced by Tarrytown New York-based TechnoVax a biotechnology developer of novel vaccines whose proprietary virus-like particle (VLP) is the centre of the research. The VLP vaccine formulations tested in animals not only were highly effective in eliciting protective antibodies with neutralizing activity equivalent to or higher than the activity present in the serum